Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AmpliPhi Advances Phage In Clinic To Address Microbial Infections

Executive Summary

Emerging Company Profile: Using cocktails of bacteriophages to attack bacterial infections, San Diego-based AmpliPhi has made progress in Phase I studies for its lead program. CEO Scott Salka explains to Mike Ward how he is looking to secure sufficient capital to support the Phase II development of AmpliPhi's lead program against chronic rhinosinusitis while advancing other product candidates.

Advertisement

Related Content

BioNotebook: Targacept, AcelRx/Grunenthal, Retrophin/Transcept, AmpliPhi
AmpliPhi swallows SPS to expand bacteriophage breadth
AmpliPhi initially raises $2.7m private investment as part of planned $5m round

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register